Suzanne Grantham
Psychiatric/Mental Health · Austin, TXNPI 1427039098
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (49.4%), speaking fees and travel and lodging — rather than concentrated in one kind of arrangement. 35 manufacturers reported payments, led by AbbVie at 56.4% of the total. Among psychiatric/mental health clinicians in TX with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 850 payments — averaging $36.63 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$18K
- Otsuka America Pharmaceutical, Inc.$2K
- Alkermes, Inc.$2K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$2K
- Lundbeck LLC$1K
- Takeda Pharmaceuticals U.S.A., Inc.$959
- plus $7K from 29 others
What the payments were for
- Consulting fees$5402%
- Speaking & faculty fees$14,43846%
- Travel & lodging$6792%
- Food & beverage$15,38049%
- Education$1020%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- VRAYLAR$15,203
- Azstarys$540
- LYBALVI$488
- REXULTI$247
- Austedo XR$102
How this compares
$31,139 in reported general payments places this provider in the 95th percentile of 2,724 psychiatric/mental health providers in Texas.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| IngrezzaValbenazine Tosylate | 11 | $94,770 |
| VraylarCariprazine Hcl | 16 | $21,439 |
| TrintellixVortioxetine Hydrobromide | 26 | $16,189 |
| BelsomraSuvorexant | 26 | $13,899 |
| AuvelityDextromethorphan Hbr/Bupropion | 11 | $10,987 |
| QuviviqDaridorexant Hcl | 14 | $5,972 |
| ViibrydVilazodone Hcl | 13 | $4,441 |
| Desvenlafaxine Succinate ErDesvenlafaxine Succinate | 34 | $2,174 |
| Modafinil | 23 | $986 |
| Gabapentin | 51 | $884 |
| Lamotrigine | 63 | $784 |
| Oxcarbazepine | 12 | $646 |
| Duloxetine Hcl | 29 | $620 |
| Ropinirole Hcl | 31 | $610 |
| Aripiprazole | 13 | $597 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Neurocrine Biosciences, Inc.Ingrezza | $713 | $94,77011 claims |
| AbbVieVraylar, Viibryd | $17,565 | $25,88029 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $959 | $16,18926 claims |
| Axsome Therapeutics, Inc.Auvelity | $594 | $10,98711 claims |
| Idorsia Pharmaceuticals US IncQuviviq | $124 | $5,97214 claims |
| Lilly USA, LLCOlanzapine | $111 | $20811 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,724 psychiatric/mental health providers in Texas.
Other psychiatric/mental health in Austin
- Jaime Nelson DensonAustin$88K
- Camille WatsonAustin$34K
- Lin CaiAustin$16K
- Tracy HicksLongview$684K
- Natalie TellezHouston$602K
- Karah BrashierRichardson$567K
- Grant DavisRichardson$360K
- Victor IlogEl Paso$167K
- Lisa ShamblinGrapevine$163K
- Monique GonzalezSan Antonio$126K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.